



11-552-C100

Monoclonal Antibody to CD69 Purified Antibody (0.1 mg)

Clone:	FN50
Isotype:	Mouse IgG1
Specificity:	The antibody FN50 recognizes CD69, an lymphocyte early activation marker. HLDA IV; WS Code A 91
Regulatory Status:	RUO
Immunogen:	anti- μ -stimulated human B lymphocytes
Species Reactivity:	Human, Other not determined
Application:	Flow Cytometry Recommended dilution: 5 μ g/ml Immunohistochemistry (frozen sections) Functional Application When stimulating peripheral blood T cells, FN50 antibody together with TPA synergistically increases cell volume and RNA/DNA synthesis. Addition of FN50 to stimulated peripheral blood B cells has similar, but weaker effect.
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified by protein-A affinity chromatography
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD69 (C-type lectin domain family 2 C, CLEC2C, also known as AIM) is one of the earliest inducible cell surface molecules acquired during leukocyte activation. This glycoprotein serves as a lectin-type receptor in lymphocytes, NK cells and platelets; it is involved in lymphocyte proliferation. CD69 expression is counteracted on T cells in the AIDS stage of HIV infection, and may be also predictive for clinical response to chemoimmunotherapy.

For laboratory research only, not for drug, diagnostic or other use.

**Antibodies****References:**

- *López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, Sánchez-Madrid F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. *J Exp Med.* 1993 Aug 1;178(2):537-47.
- *Nielsen SD, Afzelius P, Ersbøll AK, Nielsen JO, Hansen JE: Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients. *Clin Exp Immunol.* 1998 Oct;114(1):66-72.
- *Pitsios C, Dimitrakopoulou A, Tsalimalma K, Kordossis T, Choremi-Papadopoulou H: Expression of CD69 on T-cell subsets in HIV-1 disease. *Scand J Clin Lab Invest.* 2008;68(3):233-41.
- *Konjević G, Jović V, Vuletić A, Radulović S, Jelić S, Spuzić I: CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. *Eur J Clin Invest.* 2007 Nov;37(11):887-96.
- *Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989); p. 293.
- *Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuerbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. *Int Immunol.* 2007 May;19(5):675-84.
- *Tomescu C, Chehimi J, Maino VC, Montaner LJ: NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. *J Immunol.* 2007 Aug 15;179(4):2097-104.
- *Hrdinka M, Dráber P, Stepánek O, Ormsby T, Otáhal P, Angelisová P, Brdicka T, Paces J, Horejsí V, Drbal K: PRR7 is a transmembrane adaptor protein expressed in activated T cells involved in regulation of T cell receptor signaling and apoptosis. *J Biol Chem.* 2011 Jun 3;286(22):19617-29.
- *Ohradanova-Repic A, Machacek C, Charvet C, Lager F, Le Roux D, Platzer R, Leksa V, Mitulovic G, Burkard TR, Zlabinger GJ, Fischer MB, Feuillet V, Renault G, Blüml S, Benko M, Suchanek M, Huppa JB, Matsuyama T, Cavaco-Paulo A, Bismuth G, Stockinger H: Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances. *Front Immunol.* 2018 Apr 27;9:852.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz